The
global anxiety disorders and depression treatment market was valued
at USD 22.5 billion in 2013 and is expected to reach USD 18.2 billion
in 2020, at a CAGR of (1.25%) from 2014 to 2020.
Browse
Anxiety Disorders and Depression Treatment Market Report with Full
TOC at
http://www.transparencymarketresearch.com/anxiety-disorders-depression-treatments.html
Anxiety
is a biological reaction to stress, trauma and fear, which can be
experienced by anyone in their lifetime, whereas depression is a
mental state of low mood and aversion to daily activities that can
affect an individual’s feelings, thoughts, sense of well-being and
behavior. Depression affects 10% to 15% men and about 10% to 25%
women. According to the World Health Organization (WHO), to date,
over 350 million people have been affected by depression globally.
The Anxiety and Depression Association of America revealed that at
present approximately 40 million people in the U.S. are suffering
from anxiety disorder and treating these patients costs around USD 42
billion each year. Thus, high prevalence of anxiety disorders and
depression helped the market to transform itself into a billion
dollar industry. However, the current scenario indicates that the
overall anxiety disorders and depression treatment market would
decline due to patent expiry of major antidepressants, weak pipeline
of novel drugs and increasing number of generic drug variants.
The
anxiety disorders and depression treatment market has been segmented
based on the drug classes commonly used for the treatment of various
types of anxiety disorders and depression such as selective serotonin
reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs),
serotonin-norepinephrine reuptake inhibitors (SNRIs), tetracyclic
antidepressants (TeCA), monoamine oxidase inhibitors (MAOIs),
benzodiazepines, atypical antipsychotics, anticonvulsants and beta
blockers. SNRIs accounted for the largest share of over 30% of the
depression treatment market in 2013. However, the segment is expected
to witness a decline in revenue in the near future, reporting a CAGR
of 14.2% from 2012 to 2016 and a CAGR of 4.3% from 2016 to 2020.
Increasing influx of generic formulations as well as patent expiry of
leading branded formulations such as Cymbalta, Lexapro and Effexor XR
are some of the major factors that would negatively affect the growth
of the segment. Moreover, with the loss of patent exclusivity,
generics would offer physicians a broad range of affordable
medications to prescribe, thereby significantly reducing the overall
size of the anxiety disorders and depression treatment market. Hence,
the future growth of the market would depend on commercialization of
novel drugs for new indications.
Major
pipeline drugs identified and expected to be launched during the
forecast period from 2014 to 2020 include Brintellix
[(Vortioxetine-Lu AA21004) (Lundbeck and Takeda)], Brexpiprazole
[(OPC-34712) (Otsuka)] and ALKS-5461 [(FDC-buprenorphine and
samidorphan) (Alkermes plc)]. The positive clinical trial outcomes of
these drugs and anticipated commercialization during the forecast
period are expected to fuel the growth of antidepressants and
anxiolytic drugs market in the near future.
Request
for customization of this report
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1199
Geographically,
North America accounted for the largest share of the anxiety
disorders and depression treatment market in 2013 (over 35%). The
U.S. accounted for the highest share of the revenue for each drug
class due to the presence of one or more branded formulations that
influenced the market dynamics significantly. However, the anxiety
disorders and depression treatment market in the U.S. is currently
saturated due to the presence of cheap generic products and several
antidepressant drugs available on prescription for the same
indication. Hence, the region is expected to witness a negative CAGR
throughout the forecast period from 2014 to 2020. Asia Pacific is
estimated to witness an appreciable growth rate (0.02%) due to
various factors such as positive marketing approval for novel
medicines, growing geriatric population and presence of a large
population base in the region. Additionally, strong economic growth
in countries such as China, Japan, New Zealand and Australia would
contribute to the growth of the market in Asia Pacific.
The
market displays intense competitive rivalry among existing players,
as currently the market for antidepressant and anxiolytic drugs is
highly fragmented comprising both large and small manufacturers.
Major market players include AstraZeneca plc, Eli Lilly and Company,
Forest Laboratories, Inc., H. Lundbeck A/S, GlaxoSmithKline plc,
Johnson & Johnson and Merck & Co., Inc. Eli Lilly and Company
held the largest share of over 30% of the total anxiety disorders and
depression treatment market in 2013. Product efficacy,
differentiation, safety, well-developed distribution networks, and
supply capabilities played a major role in determining the market
position of the company.
Browse
press Release Anxiety Disorders and Depression Treatment Market
http://www.transparencymarketresearch.com/pressrelease/anxiety-disorders-depression-treatments.htm
Browse
the full Anxiety Disorders and Depression Treatment Market [Drug
Classes: SSRIs, SNRIs, Benzodiazepines, Beta Blockers, TCAs, TeCAs,
Atypical Antipsychotics, Anticonvulsants and MAOIs] - Global Industry
Analysis, Pipeline Analysis, Size, Share, Growth, Trends and
Forecast, 2014 - 2020 report at
http://www.transparencymarketresearch.com/anxiety-disorders-depression-treatments.html
The
global anxiety disorders and depression treatment market has been
segmented as follows:
Anxiety
Disorders and Depression Treatment Market, by Drug Class
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Atypical Antipsychotics
- Tricyclic Antidepressants (TCAs)
- Tetracyclic Antidepressants (TeCAs)
- Monoamine Oxidase inhibitors (MAOIs)
- Benzodiazepines
- Beta-Blockers
- Anticonvulsants
Anxiety
Disorders and Depression Treatment Market, by Geography
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
Browse
all Pharmaceutical Market Research Reports @
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About
Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We are
privileged with highly experienced team of Analysts, Researchers, and
Consultants, who use proprietary data sources and various tools and
techniques to gather, and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Sheela
AK
90
State Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
No comments:
Post a Comment